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Abstract
Daratumumab is a human monoclonal antibody that targets CD38, a cell surface protein that is overexpressed on
multiple myeloma (MM) cells. Preclinical studies have shown that daratumumab induces MM cell death through
several mechanisms, including complement-dependent cytotoxicity (CDC), antibody-dependent cell-mediated
cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and apoptosis. Given the encouraging
efficacy and acceptable safety profile of daratumumab demonstrated in clinical trials, daratumumab has emerged as
a novel treatment option for myeloma and became the first monoclonal antibody approved by the FDA for the
treatment of MM.
Background
Advances in the treatment of multiple myeloma (MM),
particularly the development of immunomodulatory
drugs (IMiDs) and proteasome inhibitors (PIs) and the
use of autologous hematopoietic stem cell transplant-
ation, have led to significant improvement in overall
survival in patients with MM [1, 2]. Nevertheless, MM
remains incurable and outcomes in the relapsed/refrac-
tory setting are very poor [3]. This underscores an
urgent need for novel agents in the treatment of MM,
especially in patients who have become refractory to
currently available therapies [4]. In recent years, the
introduction of monoclonal antibodies (mAbs) in MM
therapy, notably mAbs targeting CD38 and SLAMF7,
has been a promising step forward in improving treat-
ment outcomes [5]. Here, we provide a brief overview
of CD38 as a therapeutic target in MM and review
available preclinical and clinical data on daratumumab,
the first-in-class human anti-CD38 mAb approved for the
treatment of MM.
Targeting CD38 in multiple myeloma
CD38 is a 46-kDa type II transmembrane glycoprotein
that is expressed on lymphoid and myeloid cells and also
on non-hematopoietic tissues [6, 7]. Notably, CD38 is
highly expressed on MM cells [8]. CD38 has been found
to have multiple functions, including ectoenzymatic ac-
tivity as well as receptor-mediated regulation of cell ad-
hesion and signal transduction [7, 9]. The enzymatic
activity of CD38 involves the conversion of nicotinamide
adenine dinucleotide (NAD+) and nicotinamide adenine
dinucleotide phosphate (NADP+) to cyclic adenosine di-
phosphate ribosyl (cADPR), ADPR, and nicotinic acid
adenine dinucleotide phosphate (NAADP), substrates
necessary for regulation of intracellular calcium signaling
[6]. In initial studies investigating the receptor function
of CD38, it was found that CD38 mediates weak cell
binding to endothelium and plays a role in lymphocyte
migration, as well as exhibits functional associations
with surface molecules of T, B, and natural killer (NK)
cells [10, 11]. The role of CD38 in cellular adhesion was
further delineated with the identification of CD31 as a
cell surface ligand for CD38 on endothelial cells [12].
Deaglio et al. found that CD38/CD31 interactions
resulted in trans-membrane signaling characterized by
calcium mobilization and cytokine secretion [12].
CD38 ligation resulting in activation of T lymphocytes
was found to induce secretion of interleukin (IL)-6,
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granulocyte-macrophage colony-stimulating factor (GM-
CSF), interferon-γ (IFN-γ), and IL-10 cytokines [13]. In
other studies, CD38 ligation by agonistic mAb in NK cells
was also shown to induce calcium fluxes and tyrosine
phosphorylation, as well as induce NK effector function
including release of IFN-γ and GM-CSF and cytotoxic re-
sponses leading to granzyme and cytokine release [14, 15].
The cellular function of CD38 and its strong expression
on MM cells has made CD38 an ideal therapeutic target
for the treatment of MM.
Daratumumab in preclinical studies
Daratumumab is an immunoglobulin G1 kappa (IgG1k)
human mAb that binds to a unique CD38 epitope on
CD38-expressing cells with high affinity and was devel-
oped by the immunization of human immunoglobulin
transgenic mice with recombinant CD38 protein [16]. de
Weers et al. found that daratumumab was the only anti-
body in a panel of 42 human CD38-specific mAbs that
triggered complement-dependent cytotoxicity (CDC) of
Daudi target cells [16]. Thus, daratumumab was studied
in a series of in vitro assays and was found to induce
CDC in freshly isolated MM cells obtained from the
bone marrow of 13 previously untreated or relapsed
MM patients [16]. Furthermore, daratumumab triggered
antibody-dependent cell-mediated cytotoxicity (ADCC)
in CD38-expressing MM cell lines in peripheral blood
mononuclear cells (PBMCs) enriched for NK cells, as
well as in patient MM cells in the presence of both au-
tologous and allogeneic effector cells [16]. Importantly,
daratumumab did not induce ADCC in CD38-negative
cells, confirming its specificity. Notably, daratumumab
was effective at inducing both CDC and ADCC against
MM cells in the presence of bone marrow stromal cells,
suggesting that daratumumab is active in the bone marrow
microenvironment [16]. In vivo, daratumumab exhibited
high efficacy in interrupting tumor growth in mouse
xenograft models [16].
In further studies investigating the mechanism of action
of daratumumab, Nijhof et al. evaluated daratumumab-
induced CDC or ADCC in vitro in bone marrow samples
of 144 MM patients [17]. Of note, no difference was found
in daratumumab-induced CDC or ADCC between
newly diagnosed, relapsed/refractory, or lenalidomide-
and bortezomib-refractory MM patients, suggesting
that resistance to prior therapies might not affect the
efficacy of daratumumab [17]. Furthermore, the investiga-
tors in this study noted a significant association between
the level of CD38 expression and daratumumab-induced
CDC and ADCC. Nijhof and colleagues found all-trans
retinoic acid (ATRA) to upregulate CD38 expression, and
pre-treatment with ATRA of patient-derived MM cells
significantly increased susceptibility to daratumumab-
induced CDC and ADCC in vitro [17]. Likewise, ATRA
augmented daratumumab activity in a humanized MM
mouse model [17].
In addition to CDC and ADCC, daratumumab has also
been shown to induce antibody-dependent cellular
phagocytosis (ADCP). In a study by Overdijk and col-
leagues, daratumumab induced phagocytosis by human
macrophages in MM cell lines in vitro observed by flow
cytometry, as well as in in vivo subcutaneous and intra-
venous leukemic xenograft mouse models [18]. Moreover,
daratumumab triggered macrophage-mediated phagocyt-
osis ex vivo in patient-derived MM cell samples [18].
ADCP thus might be an important mechanism of action
of daratumumab in the bone marrow microenvironment
given that tumor-associated macrophages in the marrow
have been shown to have Fc-dependent anti-tumor func-
tion [19]. Other mechanisms of daratumumab-induced
cell death have been studied, finding that FcR-mediated
crosslinking of daratumumab induces apoptosis of CD38-
expressing tumor cells in vitro [20]. The mechanisms of
action of daratumumab are shown in Fig. 1.
Preclinical studies have also investigated daratumumab
together with other anti-myeloma agents, finding that
daratumumab activity is enhanced in combination with
agents such as lenalidomide. Given that daratumumab
induces ADCC by NK cells and lenalidomide promotes
NK cell activity, van der Veer et al. investigated daratu-
mumab combined with lenalidomide on ADCC against
MM cells [21]. In this study, van der Veer and colleagues
used PBMCs untreated or treated with lenalidomide as
effector cells against derived MM cell lines or primary
MM cells obtained from patients’ bone marrow [21]. They
found that pre-treatment of PBMCs with lenalidomide
significantly enhanced daratumumab-induced ADCC
against derived MM cell lines and primary MM cells [21].
Furthermore, the investigators treated whole bone marrow
mononuclear cells of MM patients containing plasma cells
with lenalidomide or daratumumab alone vs. in combin-
ation, finding that the combination of lenalidomide and
daratumumab was synergistic, producing a 20 % increased
effect on tumor lysis [21]. In a separate study, the syner-
gism between lenalidomide and daratumumab on ADCC
against MM cell lines was found to occur largely via NK
cell activation by lenalidomide rather than direct lenalido-
mide effect [22]. Further synergistic effect was demon-
strated in an in vivo humanized mouse model engrafted
with MM cells from a lenalidomide- and bortezomib-
refractory patient [22]. In this model, treatment with lena-
lidomide alone resulted in tumor growth compared to
treatment with daratumumab alone which suppressed
tumor growth, while lenalidomide in combination with
daratumumab resulted in tumor reduction [22]. In an-
other study, the combination of IPH2102, an anti-KIR
antibody, with daratumumab and lenalidomide enhanced
daratumumab-induced ADCC [23].
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Daratumumab in clinical trials
The promising anti-myeloma activity of daratumumab in
preclinical studies led to the initiation of phase 1/2 clin-
ical trials with daratumumab both as monotherapy and
in combination regimens. Clinical trials of daratumumab
with available data are summarized in Table 1.
Daratumumab as monotherapy
The first-in-human clinical study of daratumumab
(GEN501) was an open-label, multicenter, two-part,
phase 1/2 clinical trial of daratumumab as a single agent
in patients with relapsed or relapsed and refractory mye-
loma evaluating its safety, efficacy, and pharmacokinetics
[24]. Thirty two patients were enrolled in part 1 (dose-
escalation study), and 72 patients were enrolled in part 2
(dose-expansion study). In part 1, the patients received
daratumumab at doses of 0.005 to 24 milligrams per
kilogram (mg/kg) in 10 cohorts; no maximum tolerated
dose (MTD) was found. In the dose-expansion study, 72
patients were enrolled, and of these, 30 patients received
daratumumab at a dose of 8 mg/kg and 42 patients re-
ceived daratumumab at dose of 16 mg/kg. The median
age was 59 and 64 in the 8 mg/kg group and the 16 mg/kg
group, respectively. The dose-expansion cohort was a
heavily pre-treated population with a median of four prior
therapies in both the 8 and 16 mg/kg dosing groups, and
79 % of patients were refractory to their last therapy. The
overall response rate (ORR) was 36 % in the 16 mg/kg
group (with 2 complete responses [CRs], 2 very good par-
tial responses [VGPRs], and 11 partial responses [PRs]),
and the median duration of response (DOR) was not
reached, with a reported 12-month progression-free
survival (PFS) rate of 65 % [22]. In the 8 mg/kg group,
the ORR was only 10 % (with three PRs) with a median
DOR of 6.9 months [24]. The investigators performed a
subgroup analysis of responses based on refractoriness
to prior therapy in the 16 mg/kg group: 64 % of the pa-
tients had disease refractory to both lenalidomide and
bortezomib, and notably, the ORR among these double-
refractory patients was 33 % [24]. The median PFS was
5.6 months in the 16 mg/kg group vs. 2.4 months in
the 8 mg/kg group, and the 12-month overall survival
(OS) was 77 % in both dosing groups [24]. In this heavily
pre-treated and refractory patient population, daratumu-
mab demonstrated encouraging anti-myeloma activity as a
single agent as well as an acceptable safety profile.
Infusion-related reactions (IRRs) occurred in 71 % of pa-
tients, most during the first infusion. The majority of IRRs
were grade 1 or 2, with no treatment discontinuations due
to IRR. Some of the most common grade 1 or 2 IRRs
were pyrexia, influenza-like illness, fatigue, bronchospasm,
























Fig. 1 Daratumumab mechanisms of action. Upper left: daratumumab binds CD38, and its Fc fragment is bound by C1q, initiating complement
cascade and resulting in a MAC which leads to cell lysis and death. Upper right: daratumumab binds CD38, and its Fc fragment is then bound by
an FcR-bearing effector cell, such as a natural killer cell, leading to activation of cytotoxic processes. Bottom left: daratumumab binds CD38, and
its Fc fragment is then bound by an FcR-bearing macrophage, inducing phagocytosis. Bottom right: FcR-mediated crosslinking of daratumumab
induces direct cellular apoptosis. MM cell multiple myeloma cell, CDC complement-dependent cytotoxicity, MAC membrane attack complex,
ADCC antibody-dependent cell-mediated cytotoxicity, ADCP antibody-dependent cellular phagocytosis
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hematologic adverse events (AEs) of all grades occurring
in ≥25 % of patients in both groups were fatigue, allergic
rhinitis, pyrexia, diarrhea, upper respiratory tract infec-
tion, and dyspnea. The most common hematologic AE
was neutropenia, occurring in 12 % of patients in the
16 mg/kg cohort [24]. In pharmacokinetic analysis,
16 mg/kg was determined to be the lowest tested dose
with consistent target saturation [24].
Daratumumab was further evaluated in an ongoing
open-label, multicenter, phase II trial (SIRIUS) in pa-
tients with MM who had been treated with at least three
prior lines of therapy or were refractory to both PIs and
IMiDs [25]. In this study, patients were randomized to
receive either daratumumab at 8 or 16 mg/kg in part 1
of the study. The 8 mg/kg cohort in part 1 did not meet
criteria for dose expansion due to an ORR of only
11.1 %; thus, 16 mg/kg was the selected dose for further
assessment in part 2 of the study [25]. In total, 106 pa-
tients received daratumumab 16 mg/kg in parts 1 and 2.
The cohort had a median age of 63.5 years and a median
of five prior lines of therapy. Moreover, 95 % of patients
were refractory to the most recent PIs or IMiDs. The
ORR was 29.2 % (3 stringent complete responses [sCRs],
10 VGPRs, and 18 PRs) with a median DOR of
7.4 months [25]. Notably, ORR was 29.7 % (30/101) in
patients who were refractory to both PIs and IMiDs
and 28.6 % (20/70) in patients who were refractory to
at least three agents (bortezomib, lenalidomide, carfil-
zomib, or pomalidomide) [25]. The median PFS was
3.7 months, and 12-month OS was 64.8 % [25]. In
this study, daratumumab demonstrated a favorable
safety profile, with no treatment discontinuation due
to drug-related AEs or IRR. The safety profile of
both dosing cohorts was similar. In the 16 mg/kg
group, the most common hematologic treatment-
emergent AEs of any grade were anemia (33 %),
thrombocytopenia (25 %), neutropenia (23 %), and
some of the most common non-hematologic
treatment-emergent AEs were fatigue, nausea, and
cough. Forty two percent of patients experienced
IRR, the majority of which were grade 1 or 2. The
most common IRRs were nasal congestion, throat ir-
ritation, cough, dyspnea, chills, and vomiting.
In a combined analysis including 148 patients from
the GEN501 and SIRIUS studies, the ORR was 31 %,
and at a median follow-up of 14.8 months, the estimated
OS was 19.9 months [26]. The GEN501 and SIRIUS
trials demonstrated that daratumumab is active as
monotherapy in patients with heavily pre-treated and
relapsed/refractory myeloma (RRMM), with response
rates comparing favorably to those of previous trials
with pomalidomide or carfilzomib as monotherapy in
RRMM [27, 28]. Importantly, daratumumab appears
to maintain its anti-myeloma activity despite refrac-
toriness to prior therapies, as seen by the encouraging
ORR in patients who were refractory to both IMiDs
and PIs in both studies (33 and 29.7 % in GEN501
and SIRIUS, respectively) [24, 25]. As a result of the
SIRIUS trial, with findings in concordance with those of
GEN501, the FDA approved daratumumab on November
16, 2015, for the treatment of refractory myeloma in pa-
tients who have received at least three previous lines of
Table 1 Clinical trials of daratumumab with available data
Study NCT number
(trial name)








Clinical trials with daratumumab as monotherapy
Lokhorst et al. 2015 [22] NCT00574288 (GEN501) 1/2 30 Daratumumab (8 mg/kg) 10 – 77 2.4
42 Daratumumab (16 mg/kg) 36 65 77 5.6
Lonial et al. 2016 [23] NCT01985126 (SIRIUS) 2 106 Daratumumab (16 mg/kg) 29 – 65 3.7
Clinical trials with daratumumab in combination regimens
Plesner et al. 2015 [27] NCT01615029 1/2 32 Daratumumab (16 mg/kg) + Rd 88 – – –
Chari et al. 2015 [29]
Mateos et al. 2015 [30]
NCT01998971 1 6 Daratumumab (16 mg/kg) + VD 100a – – –
11 Daratumumab (16 mg/kg) + VTD 100b – – –
8 Daratumumab (16 mg/kg) + VMP 100c – – –
77 Daratumumab (16 mg/kg) + POM-D 59d – – –
Palumbo et al. 2016 [32] NCT02136134 (CASTOR) 3 251 Daratumumab (16 mg/kg) + VD 83e – – NRe
247 VD 63e – – 7.16e
ORR overall response rate, PFS progression-free survival, OS overall survival, NR not reached, Rd lenalidomide and dexamethasone, VD bortezomib and dexamethasone,
VTD bortezomib/thalidomide/dexamethasone, VMP bortezomib/melphalan/prednisone, POM-D pomalidomide/dexamethasone
aMedian duration of follow-up days, 193
bMedian duration of follow-up days, 164
cMedian duration of follow-up days, 267
dORR reported for 53 of 77 patients evaluable for efficacy; median duration of follow-up days, 148
eMedian follow-up months, 7.4
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therapy, including a PI and an IMiD, or who are double
refractory to a PI and IMiD.
Daratumumab in combination regimens
The enhanced anti-myeloma activity of daratumumab
in combination with other agents in preclinical trials
provided rationale for investigation of daratumumab
in combination regimens.
Daratumumab in combination with lenalidomide and
dexamethasone in patients with relapsed or relapsed and
refractory myeloma is being studied in an ongoing,
phase 1/2, open-label, multicenter trial [29]. In part 1, a
3 + 3 design dose-escalation study, daratumumab was
administered at doses of 2 to 16 mg/kg in combination
with lenalidomide and dexamethasone until disease pro-
gression, unacceptable toxicity, or up to a maximum
24 months. Part 2 was a cohort expansion study, in
which daratumumab was administered 16 mg/kg with
lenalidomide and dexamethasone. Thirteen patients in
total were enrolled in part 1, and MTD was not reached.
Preliminary efficacy data from 20 patients presented at
the 2014 American Society of Hematology (ASH) annual
meeting showed marked decrease in M protein in all pa-
tients and a very encouraging ORR of 75 % [30]. The last
patient was enrolled in the study in August 2014, and
updated efficacy analyses including a total of 32 patients
enrolled in the part 2 expansion cohort have been pre-
sented [29]. The cohort had a median of two prior lines
of therapy. The ORR was 88 %, with 11 PRs, 9 VGPRs, 1
CR, and 7 sCRs [29]. The median time to first response
was 1 month and median time to best response was
4.5 months, indicative of deepening responses over time
[29]. The median duration of follow-up was 7.8 months,
and the median DOR was not reached, with 93 % of re-
sponders remaining progression-free at time of analysis
[29]. In this study, some of the most frequent reported
treatment-emergent AEs were neutropenia, muscle
spasms, cough, diarrhea, and fatigue. Grade 3 or 4 neutro-
penia was reported in 75 % of patients. Fifty six percent of
patients had mild to moderate IRR, which were most
commonly cough, allergic rhinitis, nausea, vomiting, and
dyspnea. Of two patients who had grade 3 IRR, one pa-
tient discontinued the study due to laryngeal edema.
Daratumumab is also under investigation in com-
bination with other MM backbone regimens in an on-
going, open-label, four-arm, multicenter, phase 1b study
[31, 32]. The four arms of the study include daratumumab
(at a dose of 16 mg/kg) in combination with the following
regimens: bortezomib/dexamethasone (VD), bortezomib/
thalidomide/dexamethasone (VTD), bortezomib/melpha-
lan/prednisone (VMP), and pomalidomide/dexametha-
sone (POM-D). Inclusion criteria for each of the arms
are as follows: VD and VTD arm (newly diagnosed
MM, irrespective of transplant eligibility); VMP arm
(newly diagnosed MM, transplant ineligible); and POM-D
arm (relapsed/refractory to two or more lines of therapy
including two or more consecutive cycles of lenalidomide
and bortezomib) [32]. Preliminary efficacy results in newly
diagnosed MM patients treated with daratumumab
(DARA) in combination with VD (n = 6), VTD (n = 11),
and VMP (n = 8) were reported by Mateos et al., with an
ORR of 100 % in each arm (DARA + VD: 3 PRs, 3 VGPRs;
DARA + VTD arm: 7 PRs, 2 VGPRs, and 1 CR; DARA +
VMP: 4 PRs, 4 VGPRs) [32]. Median duration of follow-up
days was 193, 164, and 267 days for DARA + VD, DARA +
VTD, and DARA + VMP, respectively [32]. Chari et al. re-
ported an updated efficacy analysis of the DARA + POM-
D arm at the 2015 ASH annual meeting [31]. A total of 77
patients were enrolled (enrollment ongoing) at the time of
the report in the POM-D arm, with median number of 3.5
prior therapies. Of the cohort, 65 % were refractory to both
a PI and IMiD. Of the 77 patients enrolled, 53 were evalu-
able for efficacy. The ORR was 58.5 %, with 3 sCRs, 1 CR,
12 VGPRs, and 15 PRs [31]. After a median follow-up of
148 days, 4/31 responders progressed [31]. Notably, the
combination of daratumumab with POM-D exhibited re-
markable efficacy among 40 evaluable double-refractory
patients, with a 57.5 % ORR [31]. In the POM-D arm, 61 %
of patients experienced IRR, which were most commonly
chills, cough, and dyspnea. Otherwise, no significant
additional toxicity was noted when DARA was added
to POM-D. Some of the most common AEs of any grade
were neutropenia, anemia, fatigue, cough, nausea, dys-
pnea, and diarrhea. Grade 3 or 4 AEs occurring in >10 %
of patients were all hematologic toxicities (neutropenia
[50.6 %], anemia [20.8 %], leukopenia [15.6 %], and
thrombocytopenia [10.4 %]).
The remarkable efficacy of DARA in combination
with both lenalidomide/dexamethasone and POM-D in
RRMM and in combination with backbone regimens in
newly diagnosed MM has provided rationale for initiation
of phase III trials. MMY3003 (POLLUX) and MMY3004
(CASTOR) are currently ongoing randomized, open-label,
multicenter, phase III trials for patients with relapsed or
refractory MM, in which MMY3003 will compare the effi-
cacy of daratumumab in combination with lenalidomide
and dexamethasone vs. lenalidomide and dexamethasone
alone, and MMY3004 will compare the efficacy of daratu-
mumab in combination with bortezomib and dexametha-
sone vs. bortezomib and dexamethasone alone [33]. An
interim analysis of the phase III CASTOR (MMY3004)
trial presented at the 2016 American Society of Clinical
Oncology annual meeting showed that daratumumab sig-
nificantly improved ORR, PFS, and time to progression
(TTP) in combination with bortezomib and dexametha-
sone [34]. A total of 498 patients with relapsed or refrac-
tory myeloma were randomized to receive daratumumab
in combination with bortezomib and dexamethasone or
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bortezomib and dexamethasone alone. The ORR was
83 % in patients who received daratumumab, bortezomib,
and dexamethasone compared to 63 % in patients who re-
ceived bortezomib and dexamethasone alone (p < 0.0001)
[34]. With a median follow-up of 7.4 months, median
PFS and TTP in the daratumumab arm was not reached,
whereas the median PFS and TTP in the bortezomib and
dexamethasone arm was 7.16 and 7.29 months, respect-
ively [34]. The combination of daratumumab, bortezomib,
and dexamethasone significantly improved both PFS
(HR 0.39; 95 % CI, 0.28–0.53; p < 0.0001) and TTP
(HR 0.30; 95 % CI, 0.21–0.43; p < 0.001) compared to bor-
tezomib and dexamethasone alone [34]. IRR occurred
in 45 % of patients, and the most common grade 3/4
AEs were hematologic toxicities, with higher rates of
thrombocytopenia (45 vs. 33 %) and neutropenia (13
vs. 4 %) occurring in the daratumumab arm.
The efficacy of daratumumab in newly diagnosed MM
is also to be studied in a randomized, open-label, multi-
center, phase III trial (Alcyone) that will compare VMP
(bortezomib, melphalan, prednisone) vs. DARA + VMP in
patients with newly diagnosed, previously untreated MM
who are ineligible for high-dose therapy with stem-cell
transplantation [35]. In another randomized, phase III trial
(Cassiopeia), newly diagnosed transplant-eligible patients
will be treated with VTD with or without daratumumab
as induction therapy prior to transplant followed by VTD
with or without daratumumab as consolidation therapy
and then re-randomized to daratumumab maintenance
therapy vs. observation. The ongoing clinical trials of dara-
tumumab are listed in Table 2.
Daratumumab interference with laboratory testing
Daratumumab has been found to interfere with serum
protein electrophoresis (SPEP) and immunofixation elec-
trophoresis (IFE) assays due to co-migration of daratu-
mumab with patients’ M protein, particularly with IgGk
M proteins, which impedes accurate quantification of
endogenous M protein [36]. This poses a clinical prob-
lem given SPEP and IFE assays are necessary for assess-
ment of disease response in MM. A clinical assay, the
daratumumab IFE reflex assay (DIRA), has been devel-
oped to mitigate daratumumab interference with IFE
[36]. DIRA uses a mouse anti-daratumumab antibody
that binds to daratumumab and shifts the migration
of daratumumab away from the M protein [36]. The
specificity, reproducibility, and concordance of DIRA
to distinguish daratumumab mAb from endogenous M
protein were validated in a separate study [37]. The DIRA
assay has been utilized in clinical trials of daratumumab to
confirm disease response [24].
It has also been observed that the plasma of
daratumumab-treated patients demonstrates positive
antibody screens and panreactivity on blood compatibil-
ity testing as a result of daratumumab binding to CD38
on reagent red blood cells (RBCs) [38]. This finding is
clinically relevant as MM patients undergoing treatment
with daratumumab may, at some point, require blood
Table 2 Ongoing clinical trials of daratumumab in multiple myeloma
NCT number Title Phase Number Recruitment
NCT02116569 A study of daratumumab in Japanese participants with relapsed or refractory multiple myeloma 1 9 Completed
NCT02497378 A study of JNJ-54767414 (daratumumab) in combination with bortezomib and dexamethasone
(D-Vd) in Japanese participants with relapsed or refractory multiple myeloma
1 6 Recruiting
NCT02519452 A study of daratumumab with the addition of recombinant human hyaluronidase (rHuPH20)
for the treatment of participants with relapsed or refractory multiple myeloma
1 128 Recruiting
NCT02626481 Study of daratumumab in combination with dexamethasone in resistant or refractory
multiple myeloma
2 64 Recruiting
NCT02316106 A study to evaluate 3 dose schedules of daratumumab in participants with smoldering
multiple myeloma
2 120 Recruiting
NCT02419118 Monoclonal antibodies for treatment of multiple myeloma. Emphasis on the CD38 antibody
daratumumab
2/3 50 Recruiting
NCT02076009 A study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and
dexamethasone in relapsed or refractory multiple myeloma
3 571 Active, not recruiting
NCT02136134 Addition of daratumumab to combination of bortezomib and dexamethasone in participants
with relapsed or refractory multiple myeloma
3 497 Active, not recruiting
NCT02541383 A study to evaluate daratumumab in transplant eligible participants with previously untreated
multiple myeloma (Cassiopeia)
3 1080 Recruiting
NCT02252172 Study comparing daratumumab, lenalidomide, and dexamethasone with lenalidomide and
dexamethasone in participants with previously untreated multiple myeloma
3 730 Recruiting
NCT02195479 A study of combination of daratumumab and Velcade (bortezomib) melphalan-prednisone
(DVMP) compared to Velcade melphalan-prednisone (VMP) in participants with previously
untreated multiple myeloma
3 700 Recruiting
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transfusions and accurate detection of alloantibodies in
blood compatibility testing is imperative in preventing
blood transfusion reactions. Techniques by which to
ameliorate daratumumab interference with blood com-
patibility testing are being investigated. Treating reagent
RBCs with dithiothreitol (DTT), which denatures CD38,
or the addition of neutralizing agents such as anti-
idiotype antibodies against daratumumab or recombin-
ant soluble CD38 to patients’ plasma has been found to
inhibit blood compatibility testing interference [38, 39].
The results of a multicenter, international validation
study on the use of DTT to resolve daratumumab inter-
ference with blood compatibility testing were presented
at the 2015 ASH annual meeting [40]. In this study, par-
ticipating blood banks received two unknown plasma
samples, one sample with daratumumab and the other
sample with daratumumab and an unknown clinically
significant RBC antibody. The blood banks then per-
formed standard antibody screening as well as antibody
screening with DTT-treated RBCs. Of 23 participating
sites, all sites reported daratumumab interference with
standard antibody screening (gel, tube, or solid phase
testing) but no interference using DTT-treated RBCs
[40]. Using the DTT method, all 23 sites were able to
correctly identify the unknown RBC antibody [40].
As DTT is known to also denature Kell antigens,
study investigators recommend that K negative blood
be administered when using the DTT method [38, 40]. As
the use of therapeutic antibodies for the treatment of
MM increases, clinicians must remain mindful of po-
tential laboratory interference with daratumumab as
well as other mAbs.
Conclusions
Daratumumab has been well tolerated and has dem-
onstrated encouraging response rates in clinical trials
both as a single agent and in combination regimens
in the relapsed/refractory setting [24, 25, 29, 31].
Moreover, daratumumab in combination regimens has
maintained a favorable safety profile without significant
increase in toxicities [29, 31, 34]. Clinical trials with other
CD38-targeting mAbs isatuximab (or SAR650984) and
MOR202 have also shown promising results [41–43].
Phase III trials of daratumumab both in the relapsed/re-
fractory setting as well as in newly diagnosed patients
will help to elucidate the role of daratumumab in the
treatment of MM. Given the remarkable efficacy that
has been seen with daratumumab in early clinical trials,
daratumumab as well as other mAbs are likely to change
the landscape of myeloma treatment.
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